HHLR Advisors, a subsidiary of Hony Capital, adjusted its holdings, but Chinese equities still dominated.
1min read On August 14, 2023, HHLR Advisors, a subsidiary of HHLR Capital, released its quarterly portfolio summary. According to the report, as of the end of the quarter, HHLR's total holdings in the U.S. stock market fell from $4.604 billion in the first quarter to $4.054 billion, a decrease of 12%. In terms of investment strategy, HHLR continued to favor Chinese companies listed in the U.S., increasing its holdings in Alibaba, Vipshop, and other companies. At the same time, it reduced its holdings in PDD, BABA, and Baidu to realize profits.
In terms of individual stock adjustments, HHLR reduced its holdings in Micron Technology and UMC, while increasing its holdings in Apple, Google, and Meta. In the field of biopharmaceuticals, HHLR maintained its consistent investment enthusiasm.
As of the end of the quarter, HHLR's top ten holdings included a majority of Chinese companies listed in the U.S. and biopharmaceutical companies, such as PDD, BJC, Alibaba, and other companies, reflecting its focus on investment in these sectors. In general, despite market volatility, HHLR has maintained its investment strategy in Chinese companies listed in the U.S. and biopharmaceuticals.
